Subject(s)
Endotamponade/methods , Retinal Detachment/surgery , Retinal Perforations/surgery , Visual Acuity , Vitrectomy/methods , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Macula Lutea/diagnostic imaging , Macula Lutea/surgery , Male , Middle Aged , Retinal Detachment/diagnosis , Retinal Perforations/diagnosis , Retrospective StudiesSubject(s)
Retina/pathology , Retinal Hemorrhage/therapy , Tissue Plasminogen Activator/administration & dosage , Visual Acuity , Vitrectomy/methods , Aged, 80 and over , Female , Fibrinolytic Agents/administration & dosage , Fluorescein Angiography , Fundus Oculi , Humans , Injections , Retinal Hemorrhage/diagnosis , Retinal Hemorrhage/physiopathology , Tomography, Optical CoherenceABSTRACT
AIM: To assess the efficacy of intravitreal ranibizumab for the treatment of new onset inflammatory choroidal neovascularisation (iCNV), including both uveitic and idiopathic CNVs. METHODS: Single-centre, open-label, non-randomised Phase IIb clinical trial. Patients fulfilling strict entry criteria of new onset iCNV were given monthly intravitreal ranibizumab injections for 3â months. Thereafter, re-treatment was based on evidence of persisting activity. All patients completed trial follow-up. Optical coherence tomography (OCT) and best-corrected visual acuity (BCVA) were performed at every visit. Fluorescein angiography was performed at baseline, months 4 and 12. Descriptive analysis and Wilcoxon non-parametric test were performed for analysis. RESULTS: 15 patients, 10 women with a mean age of 48.8â years (range 24-85â years) were included in the study. The mean number of injections was 4.33 (range 3-7). There was a statistically significant difference in the BCVA at month 4 (p=0.001) and at month 12 (p=0.001) compared with baseline. The mean gain in BCVA at month 4 compared with baseline was 20±15.36 letters (mean±SD), and at month 12 was 21±16.97 letters. There was a statistically significant difference in the mean central subfield thickness (CST) at baseline versus month 4 (p=0.003) and month 12 (p=0.001). CONCLUSION: Patients gained vision (mean of 21 letters at 12â months) and showed reduced CST. These results support the continued use of ranibizumab in the treatment of iCNV. TRIAL REGISTRATION NUMBER: 2008-007476-19, results.
